Dogwood Therapeutics has secured a global development and commercialization license for its antiviral candidates, IMC-1 and IMC-2, from PRIDCor Therapeutics. This partnership aims to address chronic conditions such as fibromyalgia and Long-COVID, with PRIDCor taking charge of financing and executing the development of these assets. In return, Dogwood will receive a tiered royalty of up to 15% on net sales, alongside potential milestone payments and a 9% share of future capital raised by PRIDCor, capped at $100 million.

The collaboration is significant due to its potential to enhance the therapeutic landscape for infection-associated chronic illnesses. IMC-1 and IMC-2 are positioned to leverage PRIDCor’s expertise in antiviral therapies, which could lead to innovative treatment options for patients suffering from debilitating conditions like Long-COVID. The strategic focus on these assets allows Dogwood to concentrate on its lead candidate, Halneuron®, a non-opioid NaV 1.7 inhibitor, currently in Phase 2b trials for chemotherapy-induced neuropathic pain (CINP). Halneuron® has received FDA fast track designation, highlighting its potential clinical significance.

This partnership shifts the paradigm in chronic pain and neuropathy research by integrating antiviral approaches into the treatment of long-term complications arising from viral infections. The financial structure of the agreement not only supports Dogwood’s ongoing projects but also underscores a growing recognition of the interplay between viral infections and chronic pain syndromes. As the field moves forward, the successful development of IMC-1 and IMC-2 could catalyze new avenues for therapeutic interventions, ultimately enhancing healthspan and quality of life for affected patients.

Source: globenewswire.com